Skip to main content

Saqqara, Cellular Genomics to Collaborate on Drug Design

NEW YORK, Oct. 6 (GenomeWeb News) - Saqqara Consultants will collaborate with Cellular Genomics on the development of structure-based drug design utilizing Saqqara's crystallization expertise, the firms announced today.

 

Terms of the agreement were not disclosed.

 

Carlsbad, Calif.-based Saqqara specializes in applying X-ray crystallography and molecular modeling to drug discovery programs. Branford, Conn.-based Cellular Genomics applied its chemical genetics platform to in-house drug discovery efforts, as well as to collaborations with pharma and biotech companies, including Affymetrix, Eli Lilly, and Pfizer. The firm recently raised $34.9 million in a Series C private financing.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.